UPM-Kymmene Corporation said third-quarter comparable EBIT fell 8% as customer inventory cuts reduced deliveries and higher variable costs pressured results, while stronger cash flow provided a counterpoint.
Sales from continuing operations totaled €2,202 million, compared with €2,226 million in the third quarter of 2025. Comparable EBIT was €131 million, down from €142 million, and its margin narrowed to 5.9% from 6.4%. UPM identifies comparable EBIT as an alternative performance measure, and its interim report is unaudited.
Operating cash flow, including continuing and discontinued operations, reached €420 million, up from €218 million a year earlier. UPM linked the increase to improved working-capital efficiency. The company said customers cut inventories particularly heavily in its advanced materials businesses, especially in Europe. President and CEO Massimo Reynaudo said customers in some markets held back purchases, reducing deliveries.
For the first nine months of 2026, sales from continuing operations were €6,983 million, compared with €7,140 million in the same period a year earlier. Comparable EBIT rose 10% to €601 million from €545 million, and its margin increased to 8.6% from 7.6%. Total operating cash flow for the nine-month period was €645 million, versus €685 million a year earlier.
UPM forecast second-half comparable EBIT from continuing operations of €375 million to €575 million. It expects deliveries to be lower than in the first half, with moderately higher sales prices and increased variable costs. The outlook excludes UPM Plywood, which is classified as a discontinued operation.
The company said soft graphic-paper demand and excess industry capacity restricted its ability to recoup higher energy costs through prices. UPM cited those market pressures in its rationale for a planned 50-50 joint venture combining UPM Communication Papers with Sappi’s European graphic-paper business. UPM said the European Commission had reiterated serious concerns about the deal and that discussions on possible remedies had started. A final decision was expected by year-end or shortly afterward.



